Core Viewpoint - The Chinese innovative pharmaceutical sector has shown significant performance in 2025, with the Hang Seng Innovative Drug Index increasing by over 64% throughout the year, indicating a shift from narrative to actual realization in the industry [1] Group 1: Market Performance - On December 31, 2025, various indices related to the pharmaceutical sector experienced declines, with the CSI Innovative Drug Industry Index down by 0.4%, the CSI Biotech Theme Index down by 0.7%, the CSI 300 Healthcare Index down by 0.8%, the Hang Seng Hong Kong Stock Connect Innovative Drug Index down by 1.1%, and the CSI Hong Kong Stock Connect Healthcare Comprehensive Index down by 1.4% [1] - The latest scale of the Hang Seng Innovative Drug ETF (159316) has exceeded 4 billion yuan [1] Group 2: Industry Insights - According to Zhongtai Securities, the current innovative drug market differs from the period of 2019-2021, as the transition from narrative to actual realization in overseas markets has led to record-high transaction amounts, reflecting a leap in China's innovative capabilities from quantity to quality [1] - Continuous support from domestic policies for innovative drugs has been observed, including the introduction of a commercial insurance directory, which has opened up new payment avenues [1]

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index and the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index both fell by 0.8%, while the CSI Biotechnology Theme Index decreased by 0.4%, and the CSI Innovative Drug Industry Index and the CSI 300 Pharmaceutical and Health Index both declined by 0.3% [1][10][16] - Despite the overall market decline, the Hang Seng Innovative Drug ETF (159316) saw a net subscription of 22 million units throughout the day, indicating strong investor interest [1] - According to Zhongtai Securities, the current innovative drug market differs from the 2019-2021 period, as the narrative around innovative drugs has transitioned into a phase of actual realization, with transaction amounts reaching new highs, reflecting a leap in China's innovative capabilities from "quantity" to "quality" [1][3] Group 2 - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index focuses on leading companies in the Hong Kong medical and health industry, comprising 50 stocks from medical devices, biopharmaceuticals, chemical drugs, and other health sectors [4] - The CSI Innovative Drug Industry Index tracks leading A-share innovative drug companies, consisting of no more than 50 stocks involved in innovative drug research and development [6] - The CSI 300 Pharmaceutical and Health Index covers leading companies in the A-share pharmaceutical and health sector, including chemical pharmaceuticals, medical services, and medical devices, representing various segments of the future health industry [14]

Core Viewpoint - The Hong Kong innovative drug sector is experiencing a significant rise, driven by supportive government policies and a focus on high-quality development in the pharmaceutical industry [1][2]. Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 2.0% as of 11:05 AM, with notable gains in stocks such as InnoCare Pharma-B, which increased by over 7%, and Lepu Biopharma-B, Innovent Biologics, and 3SBio, each rising by over 4% [1]. - The Hang Seng Innovative Drug ETF (159316) recorded a trading volume of nearly 400 million yuan [1]. Group 2: Policy Support - Xi'an has released the "Implementation Plan for Promoting the Capacity Enhancement of the Biopharmaceutical Industry (2025-2027)," aiming to achieve breakthroughs in key drug development technologies in areas such as stem cell drugs, peptide drugs, liver-targeted innovative drugs, and anesthetics [1]. - Various regions, including Beijing, Shanghai, Chongqing, and Sichuan, have introduced policies this year to promote high-quality development in the innovative drug sector [1]. Group 3: Industry Outlook - Changjiang Securities notes that the pharmaceutical industry is experiencing a policy cyclical trend, with comprehensive support policies for the innovative drug industry being gradually implemented [1]. - The industry is entering a new cycle of policy support, with a focus on "hard innovation" assets and those with strong overseas potential [1].

Market Overview - The A-share pharmaceutical sector opened lower and continued to decline, while the Hong Kong pharmaceutical sector showed signs of recovery in the afternoon, with a significant narrowing of losses [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index fell by 0.8%, the China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index decreased by 0.9%, the China Securities Biotechnology Theme Index dropped by 1.5%, the CSI 300 Pharmaceutical and Health Index declined by 1.7%, and the China Securities Innovative Drug Industry Index fell by 1.9% [1] Fund Activity - Despite the market downturn, there was a counter-trend investment with the Hang Seng Innovative Drug ETF (159316) seeing a net subscription of approximately 20 million units throughout the day [1]

Group 1 - The Hong Kong innovative drug sector is experiencing a rebound, with the Hang Seng Innovative Drug Index rising by 1.3%, potentially ending a four-day decline [1] - Notable stocks in the sector include Kangfang Biotech, which rose over 5%, and other companies like Yimeng Biotech, Cloudtop, and Nuocheng Jianhua, which saw increases of over 3% [1] - The Hang Seng Innovative Drug ETF (159316) recorded a trading volume exceeding 500 million yuan, indicating strong investor interest [1] Group 2 - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security announced the implementation of a new "medical insurance directory" and "commercial insurance innovative drug directory" starting January 1, 2026 [1] - The medical insurance directory will add 114 new drugs, including 50 first-class innovative drugs, while the first version of the commercial insurance directory will include 19 drugs, marking a significant advancement in the multi-layered medical insurance system [1] - According to a report by Zhongtai Securities, innovative drugs remain the most important theme in the pharmaceutical sector, with recent price adjustments leading to a more reasonable valuation and increased investment safety margins and return potential [1] Group 3 - The Hang Seng Innovative Drug Index is the first index with a "purity" of 100% focused on innovative drug companies in Hong Kong, and the Hang Seng Innovative Drug ETF (159316) is currently the only product tracking this index [1] - This ETF provides investors with a convenient way to capitalize on investment opportunities within the innovative drug sector [1]

Core Viewpoint - The pharmaceutical sector is experiencing volatility, with Hong Kong stocks continuing to adjust while A-share pharmaceutical stocks saw a slight rebound in the afternoon. The overall market indices for innovative drugs and biotechnology are mixed, indicating varied investor sentiment in the sector [1]. Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index and the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index both declined by 0.7% [1]. - The CSI Innovative Drug Industry Index increased by 0.2%, while the CSI Biotechnology Theme Index rose by 0.3% [1]. - The CSI 300 Pharmaceutical and Health Index saw a gain of 0.4%, reflecting continued capital inflow into the sector [1]. Group 2: Fund Flows - The Hang Seng Innovative Drug ETF (159316) attracted a total of 140 million yuan in the previous two trading days, with an additional net subscription of nearly 10 million shares today [1]. Group 3: Policy Updates - The National Medical Insurance Drug List for 2025 and the first version of the Commercial Health Insurance Innovative Drug List (2025) will be released on December 7, marking the 8th adjustment since the establishment of the National Medical Insurance Bureau [1]. - A total of 114 new drugs will be added to the list, including 50 first-class innovative drugs, targeting key areas such as cancer, chronic diseases, mental health, rare diseases, and pediatric medications [1].

Group 1 - The Hong Kong innovative drug sector showed strength in early trading, with companies like Kangfang Biopharma and Zai Lab rising over 3% [1] - The Hang Seng Innovative Drug ETF (159316) saw its index increase by over 1%, reflecting positive market sentiment [1] - Chinese innovative drug development is becoming a significant global player, with increasing overseas licensing transactions driving growth in the sector [1] Group 2 - The pharmaceutical industry is entering a critical phase characterized by "innovation realization + global layout," supported by population and domestic demand, as well as comprehensive manufacturing capabilities [1] - Companies are actively exploring diverse overseas expansion paths, indicating a strategic shift towards international markets [1] - By 2026, opportunities in innovative commercialization, global breakthroughs, policy optimization, and industry mergers and acquisitions are expected to emerge [1] Group 3 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index is one of the first "pure" 100% innovative drug indices, accurately reflecting the overall performance of China's innovative drug companies [1] - The Hang Seng Innovative Drug ETF (159316) is currently the only product tracking this index, providing investors with a convenient way to seize industry development opportunities [1]

Group 1 - The pharmaceutical sector experienced a decline today, with the China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index down by 1.3%, the Hang Seng Hong Kong Stock Connect Innovative Drug Index down by 1.4%, the CSI 300 Pharmaceutical and Health Index down by 1.5%, the CSI Innovative Drug Industry Index down by 1.6%, and the CSI Biotechnology Theme Index down by 1.8% [1] - Huachuang Securities stated that the fundamental reason for the pharmaceutical industry's ability to reach new highs despite ongoing challenges is the continuous demand for pharmaceuticals and the increasing number of unmet needs, along with pharmaceutical companies continuously increasing R&D investments to meet these demands [1] - China has become a significant participant in global innovative drug R&D, with overseas licensing heat continuing to rise year after year, marking the pharmaceutical industry’s entry into a revenue era driven by innovation [1] Group 2 - The index focuses on leading innovative drug companies in the A-share market, consisting of no more than 50 stocks involved in innovative drug R&D, gathering the main players in A-share innovative drugs [5] - The index has seen a decline of 1.6%, with a rolling price-to-earnings ratio of 50.2 times and a valuation increase of 72.8% since its launch [6] - The biotechnology ETF tracks the CSI Biotechnology Theme Index, which focuses on leading biotechnology companies in the A-share market, consisting of no more than 50 stocks involved in gene diagnostics, biopharmaceuticals, blood products, and other human biotechnology [7] - The biotechnology index has declined by 1.8%, with a rolling price-to-earnings ratio of 54.7 times and a valuation increase of 63.4% since its launch [8] - The pharmaceutical ETF exclusively tracks the CSI 300 Pharmaceutical and Health Index, focusing on leading companies in the pharmaceutical and health industry within the CSI 300 Index, covering various segments of the future health industry [9] - The pharmaceutical index has declined by 1.5%, with a rolling price-to-earnings ratio of 30.4 times and a valuation increase of 43.1% since its launch [10]

Group 1: Market Performance - The pharmaceutical sector experienced a collective rise this week, with innovative drugs and biotechnology sectors leading the gains [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index increased by 5.7%, while the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index rose by 3.9% [1][3] - Other indices also showed positive performance, including the CSI Innovative Drug Industry Index up by 2.5%, the CSI Biotechnology Theme Index up by 2.3%, and the CSI 300 Pharmaceutical and Health Index up by 1.3% [1][3] Group 2: Industry Outlook - CITIC Securities indicates that the Chinese pharmaceutical industry has entered a critical phase of "innovation realization + global layout," supported by population and domestic demand, as well as comprehensive manufacturing capabilities [1] - Companies are actively exploring diversified overseas paths, with a focus on innovation commercialization, global breakthroughs, policy optimization, and opportunities from industry mergers and acquisitions by 2026 [1]

Core Viewpoint - The pharmaceutical sector continues its upward trend, achieving a "three consecutive days of gains" with various indices showing positive growth, indicating a robust market performance in the industry [1]. Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 1.7% [1]. - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increased by 1.2% [1]. - The CSI Innovative Drug Industry Index saw a rise of 1.1% [1]. - The CSI Biotechnology Theme Index and the CSI 300 Pharmaceutical and Health Index both grew by 0.6% [1]. Group 2: Industry Insights - CITIC Securities states that the Chinese pharmaceutical industry has entered a critical phase characterized by "innovation realization and global layout" [1]. - Key supports for the industry include population and domestic demand base, as well as comprehensive manufacturing capabilities across the entire industry chain [1]. - Companies are actively exploring diversified overseas paths [1]. - Looking ahead to 2026, opportunities are expected in innovative commercialization, global breakthroughs, policy optimization, and industry mergers and acquisitions [1].